Research Glossary

Educational information only. Not medical advice. Terms are defined for research literacy purposes only.

This peptide glossary covers key terms used across peptide, GLP-1, and nootropic research. Definitions are written for research literacy and educational reference only — not for clinical application.

A B C D
E F G H
I L M N
P R S T
V

Amino Acid Peptide: The building blocks of peptides and proteins. There are 20 standard amino acids encoded by the human genome. Peptides are chains of 2–50 amino acids; proteins are chains of 50+. The specific sequence of amino acids determines the peptide’s structure and biological activity.
AMPA Receptor Mechanism: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor — an ionotropic glutamate receptor involved in fast synaptic transmission, synaptic plasticity, and memory formation. Target of several nootropic racetam compounds as positive allosteric modulators (PAMs).
Angiogenesis Mechanism: The physiological process of new blood vessel formation from pre-existing vessels. Studied in the context of wound healing, tissue repair, and tumor biology. TB-500 and BPC-157 are both investigated for pro-angiogenic effects in preclinical models.
Assay Lab: A laboratory procedure used to measure the quantity, potency, or identity of a substance. In the peptide research context, “assay” typically refers to the analytical tests performed on compounds — HPLC for purity, mass spectrometry for identity confirmation, endotoxin assays for sterility.
BAC Water (Bacteriostatic Water) Lab: Sterile water containing 0.9% benzyl alcohol as a preservative. The standard diluent for reconstituting lyophilized research peptides. The benzyl alcohol inhibits bacterial growth, allowing multi-use vial access with syringes. Not interchangeable with plain sterile water, saline, or tap water.
BDNF (Brain-Derived Neurotrophic Factor) Mechanism: A key neurotrophin that supports the survival, growth, and differentiation of neurons. Plays critical roles in long-term potentiation (LTP), learning, memory consolidation, and neuroplasticity. Upregulation of BDNF is a proposed mechanism of action for Semax, exercise, and several other research compounds.
Bioavailability Mechanism: The fraction of an administered substance that reaches systemic circulation in active form. Most peptides have very low oral bioavailability due to degradation by digestive proteases — this is why subcutaneous injection is the primary administration route studied in research. Exceptions include orally stable fragments like BPC-157 and specific oral formulations.
BPC-157 (Body Protection Compound-157) Peptide: A 15-amino acid partial sequence derived from human gastric juice protein BPC. One of the most extensively studied research peptides, with 400+ preclinical publications primarily in rodent models. Research areas include GI mucosal repair, tendon/ligament healing, angiogenesis, and nitric oxide pathway modulation. No large-scale human RCTs completed as of 2025.
COA (Certificate of Analysis) Lab: A quality document issued by an analytical testing laboratory confirming a compound’s identity and purity. A valid COA includes the compound name, lot/batch number, testing date, methods used (HPLC, MS), purity result, and the issuing lab’s information. Batch-specific COAs from named, independently verifiable labs are the minimum evidence standard for research-grade compounds.
CJC-1295 Peptide: A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Studied for amplifying GH pulses and raising IGF-1 levels in human research subjects. Available with (DAC) or without (no-DAC/Mod GRF 1-29) a drug affinity complex that further extends half-life. Phase II human data exists.
Concentration (mg/mL) Lab: The amount of compound dissolved per unit volume of solvent. Calculated as: Peptide mass (mg) ÷ BAC water volume (mL). Used to determine draw volume from a vial for a given research amount. A 5mg peptide reconstituted in 2mL BAC water = 2.5 mg/mL = 2500 mcg/mL.
Cyclic Peptide Peptide: A peptide whose amino acid chain forms a ring structure rather than a linear sequence. Cyclic peptides are typically more resistant to enzymatic degradation than linear peptides. PT-141 (bremelanotide) is an example of an FDA-approved cyclic peptide. Often characterized by improved oral stability and longer half-life compared to linear analogs.
Degradation Lab: The chemical breakdown of a peptide from its active form. Caused by heat, light, moisture, repeated freeze-thaw cycles, oxidation, and enzymatic activity. Lyophilized peptides stored at -20°C degrade much more slowly than reconstituted solutions. Reconstituted peptides in BAC water should typically be used within 4–6 weeks when refrigerated.
Dihexa (PNB-0408) Peptide: A synthetic analog of HGF/SF (hepatocyte growth factor/scatter factor) studied for synaptogenic effects in Alzheimer’s disease animal models. Reported synaptogenic potency orders of magnitude above BDNF in preclinical assays. Entirely preclinical evidence base. No human trial data as of 2025.
Endotoxin Lab: Lipopolysaccharide (LPS) components found in the cell walls of gram-negative bacteria. A major contamination concern in injectable research compounds. Endotoxin contamination can cause fever, septic shock, and serious adverse events when injected. LAL (Limulus Amebocyte Lysate) assay is the standard test — a valid COA should include endotoxin test results for injectable-grade compounds.
Evidence Tier Regulatory: Classification system for the strength of research evidence supporting a compound’s studied effects. As used on GLP1Place: Tier I = human Phase II/III RCT data; Tier II = human observational, case series, or Phase I; Tier III = animal (in vivo) preclinical; Tier IV = cell culture (in vitro) or mechanistic only. A higher tier does not imply safety or recommend use.
FDA (Food and Drug Administration) Regulatory: The US federal agency responsible for regulating drugs, biologics, medical devices, food, and more. A compound being “FDA approved” means it has passed Phase I, II, and III clinical trials demonstrating safety and efficacy for a specific indication, and has received NDA/BLA approval. Most research peptides are not FDA approved. Never use the phrase “FDA approved” for unapproved compounds.
Freeze-Dried (Lyophilized) Lab: The standard form in which research peptides are manufactured and shipped. Lyophilization (freeze-drying) removes water under vacuum, leaving a dry powder that is stable for long-term storage at -20°C. Lyophilized peptides must be reconstituted with BAC water or another appropriate sterile diluent before use.
GIP (Glucose-Dependent Insulinotropic Polypeptide) Mechanism: An incretin hormone secreted by intestinal K-cells in response to nutrient intake. Co-agonism of both GLP-1R and GIPR (as in tirzepatide) is associated with greater metabolic effects than GLP-1R agonism alone in clinical trials. GIPR also expressed in adipose tissue, bone, and brain.
GLP-1 (Glucagon-Like Peptide-1) GLP-1: An incretin hormone produced by intestinal L-cells in response to food ingestion. Stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite. Half-life of endogenous GLP-1 is ~2 minutes due to DPP-4 degradation. GLP-1 receptor agonists (semaglutide, tirzepatide, etc.) are designed to resist this degradation.
GHRH (Growth Hormone-Releasing Hormone) Mechanism: A hypothalamic peptide that stimulates GH synthesis and release from the anterior pituitary. GHRH analogs (CJC-1295, sermorelin) are studied for their ability to amplify the body’s endogenous GH pulsatility rather than directly injecting GH.
Half-Life Mechanism: The time required for the concentration of a compound in the body to decrease by half. Endogenous GLP-1 has a half-life of ~2 minutes. Semaglutide has a half-life of ~7 days (enabling weekly dosing). Research peptides generally have short half-lives due to enzymatic degradation; chemical modifications (PEGylation, albumin binding, DAC) can extend half-life.
HPLC (High-Performance Liquid Chromatography) Lab: The primary analytical method used to determine peptide purity in research-grade compounds. Separates mixture components and quantifies each by UV absorbance. Reported as a percentage (e.g., “≥98% purity by HPLC”). Real results show natural variation — a result of exactly 100.0% is a red flag indicating a fraudulent or improperly conducted assay.
IGF-1 (Insulin-Like Growth Factor 1) Mechanism: A hormone produced primarily in the liver in response to GH signaling. Mediates many of GH’s anabolic and growth effects. Serum IGF-1 levels are commonly used as a surrogate marker for GH axis activity in GHRH research studies. Elevated IGF-1 is associated with both tissue-building and potentially oncogenic concerns at supraphysiologic levels.
Ipamorelin Peptide: A pentapeptide GH secretagogue (ghrelin receptor agonist) with high selectivity for GH release and minimal effects on cortisol and prolactin compared to older GHRPs. Studied for GH pulse amplification, body composition endpoints, and GI motility. Phase I human data exists. Commonly researched in combination with CJC-1295.
Lyophilization Lab: See Freeze-Dried. The standard manufacturing process for stable peptide formulations. Peptides in lyophilized form retain activity for months to years when stored properly (-20°C, dark, dry). Once reconstituted, stability decreases significantly and cold storage (4°C) with time limits applies.
Liraglutide GLP-1: A first-generation GLP-1 receptor agonist with a half-life of ~13 hours (requiring daily dosing). Approved as Victoza® (type 2 diabetes) and Saxenda® (obesity). SCALE Obesity trial reported ~8% mean weight reduction at 56 weeks. Precursor to longer-acting agents like semaglutide. Largest cardiovascular outcomes dataset among GLP-1 RAs outside of semaglutide.
Mass Spectrometry (MS) Lab: An analytical technique that identifies compounds by measuring the mass-to-charge ratio of ions. The gold standard for confirming peptide identity (not just purity). An HPLC purity assay tells you what percentage of the material is “something” — MS confirms that “something” is actually the compound it claims to be. Both should be present on a valid research-grade COA.
Melanocortin Receptor Mechanism: A family of G-protein coupled receptors (MC1R–MC5R) that bind α-MSH and ACTH derivatives. Involved in pigmentation (MC1R), energy homeostasis (MC3R/4R), sexual function (MC4R), and adrenal function (MC2R). PT-141 (bremelanotide) acts as an MC3R/MC4R agonist — the mechanism underlying its studied effects on sexual response.
mTOR (mechanistic Target of Rapamycin) Mechanism: A serine/threonine kinase that acts as a master regulator of cellular growth, protein synthesis, autophagy, and metabolism. mTORC1 inhibition by rapamycin is associated with lifespan extension in multiple organisms including mammals. Excessive mTOR activation is associated with cancer, metabolic disease, and accelerated aging in some research contexts.
NAD+ (Nicotinamide Adenine Dinucleotide) Mechanism: A coenzyme essential for energy metabolism, DNA repair, and sirtuin activation. NAD+ levels decline with age. Research on NMN and NR as NAD+ precursors investigates whether supplementing these precursors can meaningfully raise cellular NAD+ and whether that translates to functional benefits for aging-related endpoints.
NMN (Nicotinamide Mononucleotide) Peptide: A direct NAD+ precursor in the Preiss-Handler and salvage pathways. Multiple small human trials (2019–2024) confirm it raises blood NAD+ levels. Functional endpoint data (cognitive, physical) more limited. FDA moved to classify NMN as an IND (investigational new drug ingredient) in 2023, complicating its US supplement status. Phase II trials ongoing.
Nootropic Regulatory: An informal term coined by Corneliu Giurgea in 1972 for compounds that enhance cognitive function while being non-toxic and protective of the brain. Not a regulatory classification. Widely misapplied in marketing. On this platform, we use “nootropic” as a research category descriptor for compounds investigated for CNS-related endpoints, not as a claim of efficacy or safety.
Peptide Peptide: A chain of 2–50 amino acids linked by peptide bonds. Research peptides are synthetic versions of naturally occurring peptides or novel designed sequences studied for biological activity. Longer chains (50+ amino acids) are classified as proteins. Peptides are generally more stable than proteins but less stable than small-molecule drugs.
PT-141 (Bremelanotide) Peptide: A cyclic heptapeptide melanocortin receptor agonist. FDA approved as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women — one of the few research peptides with full FDA approval. Acts centrally via MC3R/MC4R, distinguishing it from PDE5 inhibitors which act peripherally.
Proteolysis / Proteolytic Degradation Mechanism: Enzymatic cleavage of peptide bonds by proteases (peptidases). The primary reason most peptides are not orally bioavailable — digestive enzymes in the stomach and small intestine rapidly degrade most peptide sequences. Chemically modified peptides with non-natural amino acids or cyclization can resist proteolysis.
Racetam Mechanism: A class of synthetic compounds sharing a pyrrolidone nucleus, first typified by piracetam (1964). Studied for cognitive-enhancing effects via AMPA receptor positive allosteric modulation, membrane fluidity improvement, and other proposed mechanisms. Not a single mechanism class — individual racetams differ substantially in pharmacology. Regulatory status varies by country.
Reconstitution Lab: The process of dissolving lyophilized (freeze-dried) peptide powder with a sterile diluent (typically BAC water) to create an injectable solution. Proper reconstitution technique is critical: inject BAC water down the glass wall of the vial, swirl gently (do not shake), and ensure complete dissolution before use. See the First-Timer’s Guide for full protocol.
Retatrutide GLP-1: An investigational triple incretin receptor co-agonist targeting GLP-1R, GIPR, and glucagon receptor (GCGR). Phase II trial (N=338, 48 weeks) reported up to 24.2% mean body weight reduction — the highest reported for a pharmacological weight-loss intervention as of 2025. Phase III trials ongoing as of 2025.
SC (Subcutaneous) Injection Lab: Injection into the subcutaneous tissue layer (fat) just below the skin, rather than into a vein (IV) or muscle (IM). The standard route for most research peptides. Allows slower absorption than IV and avoids the precision required for IM. Most GLP-1 RAs, growth peptides, and repair peptides are administered SC in research protocols.
Semaglutide GLP-1: A GLP-1 receptor agonist with a ~7-day half-life, enabling weekly dosing. FDA approved as Ozempic® (type 2 diabetes), Wegovy® (obesity), and Rybelsus® (oral). SELECT trial (N=17,604) demonstrated significant MACE reduction in non-diabetic overweight individuals with CVD. STEP 1 trial reported 14.9% mean weight reduction at 68 weeks.
Sermorelin Peptide: A 29-amino acid GHRH analog (the first 29 residues of endogenous GHRH). Shorter half-life than CJC-1295. Previously FDA-approved for pediatric GH deficiency (Geref®) but withdrawn for commercial reasons in 2008. Still prescribed by compounding pharmacies. Extensively studied for GH axis stimulation in aging adults.
TB-500 (Thymosin Beta-4 Fragment) Peptide: A synthetic analog of the actin-sequestering peptide thymosin β4. Studied for wound healing, angiogenesis, cardiomyocyte protection, and muscle repair in preclinical models. Human data exists primarily for wound healing applications. Acts partly by modulating actin dynamics and anti-inflammatory signaling pathways.
Thymosin Alpha-1 (Tα1) Peptide: A 28-amino acid thymic peptide that modulates T-cell differentiation and innate immune signaling via TLR (Toll-like receptor) pathways. Approved in 35+ countries (not FDA-approved in the US) for hepatitis B, hepatitis C, and as a cancer immunotherapy adjunct. Marketed as Zadaxin®. Among the most evidence-backed peptides with actual Phase III RCT data.
Tirzepatide GLP-1: A dual GLP-1/GIP receptor co-agonist. FDA approved as Mounjaro® (type 2 diabetes, 2022) and Zepbound® (obesity, 2023). SURMOUNT-1 trial (N=2,539, 72 weeks) reported 20.9% mean body weight reduction at the highest dose vs. 3.1% placebo — highest weight loss efficacy of any FDA-approved medication at time of approval.
Vial Lab: The sealed glass container in which lyophilized research peptides are shipped. Typically 2mL or 10mL with a rubber septum stopper and metal crimp cap. Vials are accessed with a syringe needle through the septum. Wipe the septum with an alcohol swab before every needle penetration. Reconstituted vials should be labeled with the reconstitution date.
Vyleesi® (Bremelanotide / PT-141) Regulatory: FDA-approved melanocortin receptor agonist for HSDD in premenopausal women. Injected SC 45 minutes before sexual activity. Approval (2019) was based on two Phase III RCTs showing clinically meaningful increases in satisfying sexual events vs. placebo. The underlying peptide (PT-141) was studied in research contexts well before approval.